localized prostate cancer
Item
low or intermediate risk localized prostate cancer:
boolean
C0600139 (UMLS CUI [1])
gleason score
Item
gleason score ≤ 7
boolean
C0332326 (UMLS CUI [1])
psa
Item
psa <20
boolean
C0138741 (UMLS CUI [1])
prostate cancer stage
Item
stage t2a or less (stage 2 only)
boolean
C0280280 (UMLS CUI [1])
prostate cancer biopsy histology
Item
<50% of biopsy cores involved with tumor (stage 2 only)
boolean
C0600139 (UMLS CUI [1,1])
C0005558 (UMLS CUI [1,2])
C0019638 (UMLS CUI [1,3])
hip replacement
Item
history of hip replacement
boolean
C0392806 (UMLS CUI [1])
inflammatory bowel disease, collagen vascular disease
Item
inflammatory bowel disease or collagen vascular disease
boolean
C0021390 (UMLS CUI [1])
C0262428 (UMLS CUI [2])
fiducial markers contraindication
Item
contraindication to fiducial marker placement
boolean
C2826325 (UMLS CUI [1,1])
C1301624 (UMLS CUI [1,2])
bleeding diathesis, anticoagulant therapy
Item
bleeding diathesis or anticoagulant therapy that cannot safely be ceased temporarily
boolean
C0005779 (UMLS CUI [1])
C0150457 (UMLS CUI [2])
trus- guided prostate biopsy adverse event
Item
severe adverse event with prior trus-guided prostate biopsy
boolean
C019480 (UMLS CUI [1,1])
C0373345 (UMLS CUI [1,2])
C0877248 (UMLS CUI [1,3])
patient refuses fiducial markers
Item
patient refuses fiducial marker placement
boolean
C2826325 (UMLS CUI [1,1])
C3242233 (UMLS CUI [1,2])
mri contraindication
Item
contraindication to mri
boolean
C0024485 (UMLS CUI [1,1])
C0522473 (UMLS CUI [1,2])
patient randomization
Item
patient randomization in profit trial (stage 2 only)
boolean
C0030705 (UMLS CUI [1,1])
C0034656 (UMLS CUI [1,2])
prostate radiotherapy
Item
patients not prescribed 78gy in 39 fractions to the prostate gland.
boolean
C0948317 (UMLS CUI [1])